Fibrogen INC

Kyntra Bio, Inc. has received the final $4 million holdback payment from AstraZeneca, concluding the sale of its China operations.

Kyntra Bio reported Q1 2026 financial results, highlighting progress in its FG-3246 and roxadustat programs, alongside a cash runway into 2028.

Kyntra Bio, Inc. received a notice from Nasdaq indicating it no longer meets continued listing requirements due to insufficient total assets and revenue, and has 45 days to submit a compliance plan.

Kyntra Bio announced its fourth quarter and full year 2025 financial results, highlighting progress in its FG-3246 and roxadustat clinical programs and a cash runway into 2028.

FibroGen rebrands as Kyntra Bio, shifting strategic focus to oncology and rare disease assets with a new Nasdaq trading symbol KYNB.

FibroGen reported third-quarter 2025 financial results, highlighted by the $220 million sale of its China operations to AstraZeneca, extending its cash runway into 2028.

Kyntra Bio, Inc. (KYNB) filed its Q1 2026 10-Q, detailing a net loss from continuing operations and strategic updates on its oncology and rare disease pipeline, including FG-3246 and roxadustat.

FibroGen reported significantly reduced net losses and advanced its key clinical programs for prostate cancer and anemia, following the divestiture of its China operations.

FibroGen reports reduced losses and significant cost cuts, but warns of substantial doubt about its ability to continue as a going concern without the pending $210 million China asset sale.

FibroGen reports Q1 2025 results, including an amendment to its financing agreement and the strategic decision to sell its China roxadustat assets to AstraZeneca.

FibroGen's Q3 2024 results show a 27% increase in revenue year-over-year, driven by product sales in China, while the company continues to manage costs and navigate a challenging financial landscape.

FibroGen's Q2 2024 results show a 32% increase in revenue compared to the same period last year, driven by roxadustat sales in China and a one-time adjustment.

Kyntra Bio, formerly FibroGen, completed the sale of its China operations for $220.4 million, significantly improving liquidity while advancing its oncology and myelodysplastic syndromes pipeline.

FibroGen's 10-K filing reveals a company in transition, balancing the potential of its oncology pipeline and roxadustat commercialization with significant financial challenges and strategic shifts.

FibroGen's 2023 annual report highlights progress in pancreatic cancer trials, roxadustat sales growth in China, and strategic pipeline advancements.

Director Maykin Ho was granted 7,000 stock options in Kyntra Bio, Inc. as part of a standard equity compensation package.

Director Jeffrey L. Edwards was granted 7,000 stock options in Kyntra Bio, Inc. with an exercise price of $7.13.

Director Michael Kauffman was granted 7,000 stock options in Kyntra Bio, Inc. as part of a standard equity compensation plan.

Director James A. Schoeneck was granted 7,000 stock options in Kyntra Bio, Inc. as part of a standard equity compensation plan.

CEO Thane Wettig reported the withholding of 198 shares of Kyntra Bio common stock to satisfy tax obligations related to restricted stock unit vesting.

Kyntra Bio CFO David DeLucia disposed of 52 shares to satisfy tax obligations related to restricted stock unit vesting.

FibroGen, Inc. is holding its 2025 Annual Meeting on June 4, 2025, and stockholders are encouraged to vote on key proposals.

FibroGen is asking stockholders to approve a reverse stock split to meet Nasdaq's minimum bid price requirement and maintain its listing.

FibroGen, Inc. is holding its annual meeting on June 5, 2024, where stockholders will vote on the election of directors, approval of the 2024 Equity Incentive Plan, executive compensation, ratification of the auditor, and the frequency of executive compensation votes.

FibroGen, Inc. announces its 2024 Annual Meeting of Stockholders to be held on June 5, 2024, featuring proposals ranging from director elections to equity incentive plan approval.

Armistice Capital, LLC and Steven Boyd have jointly reported a beneficial ownership of 9.88% in Kyntra Bio, Inc., holding 400,000 shares.

Armistice Capital, LLC and Steven Boyd have disclosed a 9.35% beneficial ownership stake in FibroGen Inc., holding 378,000 shares of common stock.

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 8.31% in FibroGen Inc., totaling 336,000 shares of common stock.

The Vanguard Group has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 4.4% in FibroGen Inc.'s common stock.

Armistice Capital, LLC and Steven Boyd have reported an 8.42% beneficial ownership stake in FibroGen Inc., holding 8,500,000 shares as of March 31, 2025.

Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 6.75% beneficial ownership stake in FibroGen, Inc., holding 6,800,000 shares as of December 31, 2024.